Vincerx Pharma, Inc.
VINC · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.01 | 0.14 |
| FCF Yield | -160.73% | -22.45% | -8.00% | -6.89% |
| EV / EBITDA | 0.50 | -2.64 | -10.43 | -11.07 |
| Quality | ||||
| ROIC | -161.37% | -324.01% | -72.18% | -39.46% |
| Gross Margin | 0.00% | 50.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.77 | 0.81 | 3.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,022,071.46% | 1,022,071.46% | 1,095,196.72% | 1,095,196.72% |
| Free Cash Flow Growth | 27.94% | 3.10% | -9.45% | 24.69% |
| Safety | ||||
| Net Debt / EBITDA | 1.33 | 0.58 | 0.17 | 0.84 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 87.72 | 0.00 | -512.00 |